SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company specializing in the research and development of new drugs for central nervous system disorders. The company also focuses on finding treatments for brain tumors, including metastatic tumors. With a Risk Rating Score of 28.5, SK Biopharmaceuticals Co., Ltd. is considered to be at a medium risk level. The company's pipeline includes drugs such as Cenobamate, Solriamfetol, and Carisbamate. Headquartered in Gyeonggi Province, SK Biopharmaceuticals has a Bio Science Research Institute located in Pangyo Techno Valley.